Its vast experience in diabetes and the amount of data collected has propelled Novo Nordisk into exploring new modalities and searching for valuable collaborators, according to the company’
The amount of patient data has skyrocketed, providing opportunities to gain a deeper understanding of diseases that are particularly complex or areas with a high level of unmet need, accord